Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,501 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00664326 | A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC | completed | Phase 2 | 49 | BayerINDUSTRY | 6 | Jan 29, 2021 | clinicaltrials |
| NCT02022917 | Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | completed | Phase 2 | 22 | Chang Gung Memorial HospitalOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT01882985 | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | completed | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01519869 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 28 | Rachel MillerOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT01798446 | A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus | completed | Phase 2 | 41 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00551070 | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2020 | clinicaltrials |
| NCT02093598 | POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus(POEM) | completed | Phase 2 | 10 | MedSIROTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03066427 | Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.(INMUNOSUN) | completed | Phase 2 | 23 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01576172 | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 159 | National Cancer Institute (NCI)NIH | 1 | Nov 12, 2020 | clinicaltrials |
| NCT02788201 | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2020 | clinicaltrials |
| NCT01297244 | A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 105 | AVEO Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 27, 2020 | clinicaltrials |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT00083941 | A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer | completed | Phase 2 | 25 | Oxford BioMedicaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT00325507 | Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma | completed | Phase 2 | 25 | Oxford BioMedicaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01498978 | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03515577 | Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery(PSMA vs AXUMIN) | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00478361 | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2020 | clinicaltrials |
| NCT00113217 | Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01266460 | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 54 | Gynecologic Oncology GroupNETWORK | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT00502307 | A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma | completed | Phase 2 | 272 | AVEO Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 1, 2020 | clinicaltrials |
| NCT01637402 | A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | completed | Phase 2 | 41 | Terence Friedlander, MDOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02125357 | Sequencing Abiraterone and Enzalutamide in mCRPC | completed | Phase 2 | 202 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT01611558 | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 13, 2020 | clinicaltrials |
| NCT04462445 | Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb(PIPELINE) | completed | Phase 2 | 25 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Jul 10, 2020 | clinicaltrials |
| NCT00853372 | AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib | completed | Phase 2 | 85 | AmgenINDUSTRY | 0 | Jul 1, 2020 | clinicaltrials |
| NCT02187302 | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | completed | Phase 2 | 115 | NewLink Genetics CorporationINDUSTRY | 2 | May 28, 2020 | clinicaltrials |
| NCT01510119 | Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | completed | Phase 1 / Phase 2 | 38 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT00305695 | Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries | completed | Phase 2 | 160 | Gynecologic Oncology GroupNETWORK | 1 | Mar 24, 2020 | clinicaltrials |
| NCT01716715 | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02315430 | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00979992 | Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 2 | Feb 19, 2020 | clinicaltrials |
| NCT00478426 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 2 | Feb 17, 2020 | clinicaltrials |
| NCT01091636 | Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer | completed | Phase 2 / Phase 3 | 184 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01787331 | Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer | completed | Phase 2 | 21 | University of California, San FranciscoOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03540407 | Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma. | completed | Phase 2 | 66 | Catalysis SLINDUSTRY | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT02429193 | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA(BARRIER-P) | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Jan 13, 2020 | clinicaltrials |
| NCT01550367 | Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) | completed | Phase 1 / Phase 2 | 30 | Leonard ApplemanOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01984242 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma(IMmotion150) | completed | Phase 2 | 305 | Hoffmann-La RocheINDUSTRY | 9 | Dec 23, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT00450749 | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2019 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT02091531 | Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jan 29, 2021source: clinicaltrials